apixaban vs rivaroxaban in cancer | American Society of Hematology 202

Keyword	CPC	PCC	Volume	Score	Length of keyword
apixaban vs rivaroxaban in cancer	0.29	0.5	1402	82	33
apixaban	0.49	1	8949	37	8
vs	0.42	0.4	3336	17	2
rivaroxaban	1.89	0.1	9303	52	11
in	1.27	0.7	4988	34	2
cancer	0.97	0.9	3974	56	6

Keyword	CPC	PCC	Volume	Score
apixaban and rivaroxaban difference	1.51	1	1156	56
edoxaban vs apixaban vs rivaroxaban	1.62	0.3	2157	55
edoxaban vs rivaroxaban and apixaban	0.57	0.6	1424	83
is apixaban better than rivaroxaban	1.34	0.1	2646	71
rivaroxaban vs apixaban bleeding risk	0.92	0.4	6750	12
apixaban vs rivaroxaban in renal failure	0.83	0.6	8528	69
rivaroxaban apixaban and edoxaban	0.75	1	7053	54
apixaban vs rivaroxaban for afib	0.47	0.7	8241	79
apixaban in cancer patients	1.95	0.5	8110	88
rivaroxaban versus apixaban afib	1.57	0.2	6414	54
which is safer apixaban or rivaroxaban	1.45	0.3	5535	15
apixaban vs rivaroxaban pulmonary embolism	0.53	0.4	9017	96
apixaban vs rivaroxaban gi bleed	1.78	0.7	1302	74
apixaban vs rivaroxaban for dvt	0.11	0.7	5024	84
change from rivaroxaban to apixaban	0.67	0.8	4320	95
apixaban to rivaroxaban conversion	0.58	0.7	2277	12
bleeding risk apixaban rivaroxaban	0.51	0.3	5269	1
changing from apixaban to rivaroxaban	1.43	0.4	9285	79
rivaroxaban and apixaban cross reactivity	0.87	0.8	8058	26
rivaroxaban and colon cancer	1.04	0.9	3818	81
switching from apixaban to rivaroxaban	0.4	0.5	9613	8
apixaban vs rivaroxaban bleeding risk	0.25	0.7	5197	82
switch from rivaroxaban to apixaban	0.92	0.6	7844	84
switching from rivaroxaban to apixaban	1.22	0.1	4980	14

Search Results related to apixaban vs rivaroxaban in cancer on Search Engine

American Society of Hematology 2021 guidelines for …
ashpublications.org

https://ashpublications.org/bloodadvances/article/5/4/927/475194/American-Society-of-Hematology-2021-guidelines-for

WebFeb 11, 2021 · Recommendations 23, 24, and 25. For the short-term treatment of VTE (first 3-6 months) for patients with active cancer, the ASH guideline panel suggests DOAC (apixaban, edoxaban, or rivaroxaban) over LMWH (conditional recommendation, low … Author: Gary H. Lyman, Gary H. Lyman, Marc Carrier, Cihan Ay, Marcello Di Nisio, Lisa K. Hicks, Alok A. Khor... Publish Year: 2021

Author: Gary H. Lyman, Gary H. Lyman, Marc Carrier, Cihan Ay, Marcello Di Nisio, Lisa K. Hicks, Alok A. Khor...
Publish Year: 2021

DA: 26 PA: 47 MOZ Rank: 92

Comparative Effectiveness of Anticoagulants in Patients With …
jamanetwork.com

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2807546

WebJul 24, 2023 · Wysokinski WE, Houghton DE, Casanegra AI, et al. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous …

DA: 52 PA: 31 MOZ Rank: 16

A systematic review of apixaban in prevention and treatment
japha.org

https://www.japha.org/article/S1544-3191(21)00272-7/fulltext

DA: 88 PA: 36 MOZ Rank: 45

Apixaban for the Treatment of Venous …
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa1915103

WebMar 29, 2020 · Major guidelines recommend the use of low-molecular-weight heparin for the treatment of cancer-associated venous … Author: Giancarlo Agnelli, Cecilia Becattini, Guy Meyer, Andres Muñoz, Menno V Huisman, Jean M Connors, Alex... Publish Year: 2020

Author: Giancarlo Agnelli, Cecilia Becattini, Guy Meyer, Andres Muñoz, Menno V Huisman, Jean M Connors, Alex...
Publish Year: 2020

DA: 46 PA: 49 MOZ Rank: 51

Rivaroxaban Versus Apixaban for Treatment of Cancer …
ashpublications.org

https://ashpublications.org/blood/article/140/Supplement%201/1257/489962/Rivaroxaban-Versus-Apixaban-for-Treatment-of

WebNov 15, 2022 · We sought to assess whether rivaroxaban was associated with comparable effectiveness and safety as apixaban for CAT treatment in patients with an active …

DA: 23 PA: 44 MOZ Rank: 99

Direct Oral Anticoagulants in Cancer Patients. Time for a Change …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281117/

WebMay 2, 2020 · Direct oral anticoagulants (DOAC), which include thrombin inhibitors (dabigatran) and factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban) present a … Author: Marek Z. Wojtukiewicz, Piotr Skalij, Piotr Tokajuk, Barbara Politynska, Barbara Politynska, Anna M. ... DOI: 10.3390/cancers12051144 Publish Year: 2020 Publication: Cancers (Basel). 2020 May; 12(5): 1144.

Author: Marek Z. Wojtukiewicz, Piotr Skalij, Piotr Tokajuk, Barbara Politynska, Barbara Politynska, Anna M. ...
DOI: 10.3390/cancers12051144
Publish Year: 2020
Publication: Cancers (Basel). 2020 May; 12(5): 1144.

DA: 7 PA: 17 MOZ Rank: 3

Comparison of apixaban to rivaroxaban and enoxaparin in acute …
nih.gov

https://pubmed.ncbi.nlm.nih.gov/31378995/

WebTo provide direct comparison between apixaban and rivaroxaban in patients with acute cancer-associated venous thromboembolism (Ca-VTE), consecutive patients treated …

DA: 19 PA: 68 MOZ Rank: 41

Direct oral anticoagulants for cancer-associated venous …
ashpublications.org

https://ashpublications.org/blood/article/136/12/1433/455308/Direct-oral-anticoagulants-for-cancer-associated

WebSep 17, 2020 · Abstract. Direct oral anticoagulants (DOACs) are an emerging treatment option for patients with cancer and acute venous thromboembolism (VTE), but studies …

DA: 95 PA: 89 MOZ Rank: 27

A systematic review of apixaban in prevention and …
japha.org

https://www.japha.org/article/S1544-3191(21)00272-7/fulltext

WebJun 11, 2021 · Key Points. Background. Venous thromboembolism (VTE) is a serious and potentially life-threatening condition in patients with cancer. Such patients are 4 to 7 times more likely to develop VTE than those …

DA: 87 PA: 12 MOZ Rank: 3